Free US stock insider buying and selling tracking with regulatory filing analysis for inside information on company health. We monitor corporate insider transactions because company officers often have the best understanding of their business prospects.
As of 2026-04-16, Coherus Oncology Inc. (CHRS) trades at $1.9 per share, marking a 1.06% gain from the previous session’s close. The oncology-focused biotech stock has been trading in a tight range in recent weeks, with well-defined support and resistance levels drawing attention from technical traders. This analysis breaks down the current market context surrounding CHRS, key technical levels to monitor, and potential near-term scenarios based on current price action and sector trends. No recen
Coherus (CHRS) Stock Signal Based Trade (Bullish Momentum) 2026-04-16 - Collaborative Trading Signals
CHRS - Stock Analysis
4913 Comments
1156 Likes
1
Larraine
Daily Reader
2 hours ago
Who else is quietly observing all this?
👍 88
Reply
2
Joshie
Daily Reader
5 hours ago
The way this turned out is simply amazing.
👍 296
Reply
3
Yanahi
Active Contributor
1 day ago
Indices continue to test intraday highs with moderate volume.
👍 237
Reply
4
Dystinee
Active Contributor
1 day ago
Balanced approach, easy to digest key information.
👍 89
Reply
5
Vagmi
Returning User
2 days ago
A retracement could provide a better entry point for long-term investors.
👍 149
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.